Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Oncolytics Biotech Inc.
  6. News
  7. Summary
    ONC   CA6823108759

ONCOLYTICS BIOTECH INC.

(ONC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oncolytics Biotech : to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

05/14/2021 | 07:26am EDT

SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference, which is taking place virtually from May 18-20, 2021. Presentation details are listed below.

Presenter: Dr. Matt Coffey, President & Chief Executive Officer of Oncolytics Biotech Inc.

Date: Wednesday, May 19, 2021

Time: 5:25 pm Eastern Daylight Time

The Company will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please contact your RBC representative or email tim@lifesciadvisors.com.

A live webcast of the fireside chat will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for two weeks.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype-turning 'cold' tumors 'hot'-through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as 'forward-looking statements'). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Contact:

Jon Patton

Director of IR & Communication

T: +1-858-886-7813

E: jpatton@oncolytics.ca

Investor Relations Oncolytics

Timothy McCarthy

LifeSci Advisors

T: +1-917-679-9282

E: tim@lifesciadvisors.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ONCOLYTICS BIOTECH INC.
05/21ONCOLYTICS BIOTECHá : Announces Clinical and Biomarker Data Demonstrating Clinic..
AQ
05/20ONCOLYTICS BIOTECHá : reg; Announces Clinical and Biomarker Data Demonstrating C..
PU
05/20ONCOLYTICS BIOTECH BRIEF : Up 5% On TSX After Announcing Clinical and Biomarker ..
MT
05/20ONCOLYTICS BIOTECHá : Up 8% In US Pre-Market As Announces Clinical and Biomarker..
MT
05/20ONCOLYTICS BIOTECH BRIEF : Up 8% In US Pre-Market As Announces Clinical and Biom..
MT
05/20ONCOLYTICS BIOTECH BRIEF : Announces Clinical and Biomarker Data Demonstrating C..
MT
05/20ONCOLYTICS BIOTECHá : reg; Announces Clinical and Biomarker Data Demonstrating C..
AQ
05/14ONCOLYTICS BIOTECHá : to Participate in Virtual Fireside Chat at the 2021 RBC Ca..
AQ
05/12ONCOLYTICS BIOTECHá : reg; Announces Voting Results from the Annual General Meet..
PU
05/11ONCOLYTICS BIOTECHá : Announces Voting Results from the Annual General Meeting o..
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -26,4 M -21,7 M -21,7 M
Net Debt 2021 - - -
P/E ratio 2021 -7,30x
Yield 2021 -
Capitalization 196 M 161 M 161 M
Capi. / Sales 2021 -
Capi. / Sales 2022 23,7x
Nbr of Employees -
Free-Float 98,5%
Chart ONCOLYTICS BIOTECH INC.
Duration : Period :
Oncolytics Biotech Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCOLYTICS BIOTECH INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 7,25 CAD
Last Close Price 3,59 CAD
Spread / Highest target 137%
Spread / Average Target 102%
Spread / Lowest Target 67,1%
EPS Revisions
Managers and Directors
NameTitle
Matthew C. Coffey President, CEO, COO & Director
Kirk J. Look Chief Financial Officer
Wayne F. Pisano Chairman
Thomas C Heineman Global Head-Clinical Development & Operations
Angela Holtham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCOLYTICS BIOTECH INC.19.21%161
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416